

LONG-ACTING CABOTEGRAVIR+RILPIVIRINE (CAB+RPV) IN OLDER ADULTS: POOLED PHASE 3 WEEK 96 RESULTS

Authors:

Elliot ER,¹ Benn PD,¹ Clark A,¹ Polli JW,² Garside L,³ Roberts J,⁴ D'Amico R,² Ford SL,⁵ Vanveggel S,⁶ Baugh B,⁷ Van Wyk JA¹, Cowley D⁸

¹ViiV Healthcare, Brentford, United Kingdom; ²ViiV Healthcare, Research Triangle Park, NC, United States; ³GlaxoSmithKline, London, United Kingdom; ⁴GlaxoSmithKline, Mississauga, ON, Canada; ⁵GlaxoSmithKline, Research Triangle Park, NC, United States; ⁶Janssen Research & Development, Beerse, Belgium; ⁷Janssen Research & Development, Titusville, NJ, United States; ⁸ ViiV Healthcare, Abbotsford, VIC, Australia

Background:

CAB+RPV is the first complete long-acting (LA) regimen for maintaining HIV-1 virologic suppression. Successful HIV treatments have increased the proportion of people living with HIV aged ≥ 50 years. Similar outcomes with CAB+RPV LA have been observed regardless of age through Week (W) 48. Here, longer-term outcomes through W96 are presented by age group.

Methods:

Data from the Antiretroviral Therapy as Long Acting Suppression (ATLAS) every 2 Months (ATLAS-2M) and First Long-Acting Injectable Regimen studies were pooled and stratified by age (< 50 or ≥ 50 years). Data from ATLAS-2M participants who transitioned from CAB+RPV in ATLAS were excluded. W96 efficacy endpoints were proportion of participants with plasma HIV-1 RNA ≥ 50 (virologic non-response) and < 50 copies/mL (virologic suppression). Incidence of confirmed virologic failure (CVF; two consecutive measurements of ≥ 200 copies/mL) and safety through W96 were also assessed.

Results:

Participants aged < 50 ($n=983$) and ≥ 50 ($n=237$) years were randomized to receive CAB+RPV LA every 4 or 8 weeks, or continue oral antiretroviral therapy (ART); 18 (LA, $n=17$; oral ART, $n=1$) were ≥ 65 years. Participants ≥ 50 years generally had more comorbidities and co-medications at baseline vs < 50 years. Virologic outcomes were similar across arms and age groups; virologic suppression rates were high (87–94%) and non-response rates were low (1–3%). CVF rates were similarly low across arms and age groups (1–2%). Frequencies of drug-related adverse events (AEs), serious AEs, and AEs leading to withdrawal were comparable between age groups for both LA regimens. Injection site reactions were similar across age groups, most being mild to moderate. Outcomes were broadly comparable for participants ≥ 65 years.

Conclusions:

CAB+RPV LA demonstrated high efficacy and acceptable safety and tolerability in participants aged < 50 and ≥ 50 years at W96. These data support CAB+RPV LA as a complete maintenance regimen in adults irrespective of age.

Disclosure of Interest Statement:

ERE, PDB, AC, JWP, RD, JAVW and DC are employees of ViiV Healthcare and may own stock in GlaxoSmithKline. LG, JR and SLF are employees of and may hold stock in GlaxoSmithKline. SV and BB are employees of and may hold stock in Janssen Pharmaceutica. This study was funded by ViiV Healthcare.